Novozymes Biopharma’s Recombumin and albucult products are the first to comply with the new excipient monograph standard for recombinant human albumin, published in the U.S. Pharmacopoeia – National Formulary (USP-NF). First published in November 2008, the monograph has become official. The use of these products is intended to ease the regulatory process for customers and set the industry benchmark for recombinant human albumin. Recombumin offers the stabilizing and formulation be...